Y Intercept Hong Kong Ltd Has $839,000 Position in Moderna, Inc. $MRNA

Y Intercept Hong Kong Ltd cut its stake in Moderna, Inc. (NASDAQ:MRNA) by 96.4% during the 1st quarter, Holdings Channel.com reports. The firm owned 16,510 shares of the company’s stock after selling 444,343 shares during the period. Y Intercept Hong Kong Ltd’s holdings in Moderna were worth $839,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

A number of other hedge funds also recently modified their holdings of MRNA. MUFG Securities EMEA plc bought a new stake in shares of Moderna during the 2nd quarter worth about $28,000. Flagship Harbor Advisors LLC acquired a new position in Moderna in the 4th quarter valued at about $31,000. Canton Hathaway LLC bought a new position in Moderna in the 1st quarter valued at about $31,000. Cromwell Holdings LLC raised its holdings in Moderna by 39.7% in the 4th quarter. Cromwell Holdings LLC now owns 1,200 shares of the company’s stock valued at $35,000 after acquiring an additional 341 shares during the period. Finally, EverSource Wealth Advisors LLC lifted its position in Moderna by 148.3% during the second quarter. EverSource Wealth Advisors LLC now owns 1,341 shares of the company’s stock worth $37,000 after acquiring an additional 801 shares during the last quarter. Institutional investors and hedge funds own 75.33% of the company’s stock.

Analysts Set New Price Targets

MRNA has been the subject of a number of research analyst reports. The Goldman Sachs Group boosted their price objective on Moderna from $43.00 to $49.00 and gave the stock a “neutral” rating in a report on Friday, May 1st. Piper Sandler increased their target price on Moderna from $69.00 to $77.00 and gave the stock an “overweight” rating in a research note on Friday, June 26th. Morgan Stanley lifted their price target on Moderna from $33.00 to $39.00 and gave the stock an “equal weight” rating in a report on Wednesday. Bank of America boosted their price target on Moderna from $34.00 to $38.00 and gave the company an “underperform” rating in a research note on Tuesday, July 7th. Finally, Barclays boosted their price target on Moderna from $25.00 to $48.00 and gave the company an “equal weight” rating in a research note on Thursday, April 2nd. Two research analysts have rated the stock with a Buy rating, ten have assigned a Hold rating and five have given a Sell rating to the company. According to MarketBeat.com, Moderna presently has an average rating of “Reduce” and an average target price of $38.27.

Insider Buying and Selling at Moderna

In related news, President Stephen Hoge sold 53,336 shares of the stock in a transaction that occurred on Monday, June 15th. The stock was sold at an average price of $51.37, for a total transaction of $2,739,870.32. Following the sale, the president owned 1,483,848 shares of the company’s stock, valued at $76,225,271.76. This represents a 3.47% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, insider Shannon Thyme Klinger sold 3,471 shares of the firm’s stock in a transaction on Thursday, June 4th. The stock was sold at an average price of $50.00, for a total value of $173,550.00. Following the transaction, the insider owned 67,468 shares in the company, valued at approximately $3,373,400. This trade represents a 4.89% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Insiders have sold a total of 125,088 shares of company stock valued at $6,193,713 in the last three months. Corporate insiders own 10.80% of the company’s stock.

Moderna Price Performance

Shares of Moderna stock opened at $68.27 on Monday. Moderna, Inc. has a twelve month low of $22.28 and a twelve month high of $85.60. The company has a quick ratio of 2.35, a current ratio of 2.41 and a debt-to-equity ratio of 0.08. The company has a 50-day simple moving average of $56.20 and a two-hundred day simple moving average of $49.77. The stock has a market capitalization of $27.09 billion, a price-to-earnings ratio of -8.38 and a beta of 0.94.

Moderna (NASDAQ:MRNA) last posted its quarterly earnings data on Friday, May 1st. The company reported ($3.40) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($3.02) by ($0.38). Moderna had a negative net margin of 143.55% and a negative return on equity of 26.64%. The business had revenue of $389.00 million during the quarter, compared to the consensus estimate of $236.37 million. During the same period in the prior year, the firm earned ($2.52) EPS. The business’s revenue for the quarter was up 260.2% on a year-over-year basis. Analysts forecast that Moderna, Inc. will post -6.56 EPS for the current year.

Trending Headlines about Moderna

Here are the key news stories impacting Moderna this week:

• Positive Sentiment: Moderna won a European Commission contract to supply its RSV vaccine to six countries, with the deal covering up to 24 million doses. That gives the company a meaningful commercial win and supports expectations for vaccine revenue growth. Moderna wins EU contract for RSV vaccine supply
• Positive Sentiment: RBC Capital raised its price target on Moderna to $45 from $38, signaling improved analyst sentiment ahead of the company’s next earnings update. RBC Capital Raises its Price Target on Moderna (MRNA)
• Positive Sentiment: Options activity surged, with investors buying 77,577 call options, about 45% above normal volume. Heavy call buying often suggests traders are positioning for more upside.
• Neutral Sentiment: Moderna said it will report second-quarter 2026 results on July 31 and hold a conference call to provide a corporate update. Moderna to Report Second Quarter 2026 Financial Results on Friday, July 31, 2026
• Neutral Sentiment: Media coverage highlighted Moderna’s mRNA flu vaccine progress, including the possibility it could be ready this fall, but distribution and access may still be an issue. Moderna’s mRNA Flu Vaccine Could Be Ready This Fall. Getting It May Be Another Story.
• Negative Sentiment: Shares also fell during a broader biotech selloff, which may have pressured Moderna along with peers despite the company-specific positives. Moderna Drops 11%, ImmunityBio and Sarepta Therapeutics Tumble 8% in Biotech Rout

About Moderna

Moderna, Inc is a biotechnology company headquartered in Cambridge, Massachusetts, specializing in messenger RNA (mRNA) therapeutics and vaccines. The company’s platform leverages synthetic mRNA to instruct cells to produce proteins that can prevent or treat diseases. Since its founding in 2010, Moderna has advanced from early-stage research into a broad pipeline of vaccine and therapeutic candidates designed to address infectious diseases, rare genetic disorders and chronic illnesses.

Moderna’s flagship product is its mRNA-based COVID-19 vaccine, which was the first of its kind to receive emergency use authorization and later full approval in multiple jurisdictions.